Abstract
Introduction: Combining adenosine deaminase (ADA) and lymphocyte-neutrophil ratio (LNR) in pleural fluid (PF) has been shown to help differentiate exudates of tuberculous origin from others, in countries with a high prevelance of tuberculosis (TB). Since 2016 the incidence of TB in Portugal has decreased to less than 20/100.000 inhabitants, which may alter the cut-off value of these 2 markers and the usefulness of both. Aims: To ascertain the best possible cut-off value for PF ADA and LNR in pleural TB and the value of combining both markers. Methods: We conducted a cross sectional retrospective study based on the consultation of the clinical records of all patients who performed PF ADA (November 2016 to December 2018). Transudative and repeated samples were excluded. ROC curve was calculated considering a significance of 5%, and test characteristics: sensitivity (S), specificity (E), positive predictive value (PPV) and negative predictive value (NPV). Results: From a total of 200 patients, 136 were included. Patients were mainly male (60.3%); mean age of 70.4 (±15.65) years. Of total, 10 had a final diagnosis of pleural TB; 54 infectious; 45 malignant; 27 other diagnosis. Area under ROC curve was 0.808 for a cut-off value of ADA of ≥ 24.9 U/L [S 70%; E 87% (p 2.85 [S 100%; E 43% (p Conclusions: In our sample a newer and lower cut-off value of PF ADA of 24.9U/L would have a stronger power for diagnosing pleural TB. Combining both markers was only useful to exclude the disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.